Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...

ASML (NASDAQ:ASML) had its price target increased by JPMorgan Chase & Co. from $1,202.00 to $1,207.00. They currently have an overweight rating on the stock. Comerica (NYSE:CMA) had its target price ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

People-first nurse leader and burnout expert Dr. Andrea Coyle, DNP, NE-BC launches an inspiring and transformative weekly podcast, "The Shift with Dr. Andrea Coyle." As a nurse for over 30 years, Dr.

Genomics, Inc. , a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, ...

A persistent infection could explain why some people experience long COVID symptoms, according to a new study led by researchers at Brigham and Women’s Hospital. The team found evidence of persistent ...

Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $85.21 which represents a slight increase of $0.78 or 0.92% from the prior close of $84.43. The stock opened at ...

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of people around the world living with HIV.

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney.

Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand ...

The adaptation of immune cells to their local microenvironments in our body is central to tissue homeostasis and linked to ...